Arcellx Inc, a cancer immunotherapy developer, has filed Form S-1 Registration Statement on January 14, 2022 with the U.S. Securities and Exchange Commission to raise up to $100 million IPO. Pricing terms are yet to announce.
The company is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. Their mission is to advance humanity by engineering cell therapies that are safer, more effective and more broadly accessible.
The Gaithersburg, Maryland-based company was founded in 2014 and plans to list on the Nasdaq Global Market under the symbol “ACLX.” Arcellx filed confidentially on May 1, 2020. BofA Securities, SVB Leerink, Barclays, and William Blair are underwriters of the IPO.
The company engages Wilson Sonsini Goodrich & Rosati, Professional Corporation as US Securities Counsel, and Ernst & Young LLP as Independent Auditor.
#ipo #Nasdaq #Arcellx #cancer #immunotherapy #diseasesd
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected]
